RPg Family Wealth Advisory LLC Acquires New Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

RPg Family Wealth Advisory LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 81 shares of the medical research company’s stock, valued at approximately $50,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. LRI Investments LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $127,000. Sanibel Captiva Trust Company Inc. grew its holdings in Thermo Fisher Scientific by 16.7% during the 1st quarter. Sanibel Captiva Trust Company Inc. now owns 1,828 shares of the medical research company’s stock worth $1,062,000 after acquiring an additional 262 shares in the last quarter. Community Trust & Investment Co. raised its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Community Trust & Investment Co. now owns 33,455 shares of the medical research company’s stock valued at $19,444,000 after buying an additional 104 shares in the last quarter. PGGM Investments boosted its position in shares of Thermo Fisher Scientific by 0.8% during the 1st quarter. PGGM Investments now owns 198,517 shares of the medical research company’s stock worth $115,380,000 after acquiring an additional 1,585 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Thermo Fisher Scientific by 245.9% during the first quarter. Cetera Investment Advisers now owns 56,914 shares of the medical research company’s stock worth $33,079,000 after purchasing an additional 40,460 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the sale, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.7 %

Shares of NYSE:TMO opened at $521.67 on Thursday. The company has a fifty day simple moving average of $569.98 and a 200 day simple moving average of $578.78. The firm has a market cap of $199.54 billion, a PE ratio of 32.71, a price-to-earnings-growth ratio of 3.40 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $480.57 and a 12-month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted $5.69 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TMO shares. TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Finally, Bernstein Bank boosted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.